FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

COCHRANE HAYWOOD D 		2. Issuer Name and Ticker or Trading Symbol

Midatech Pharma US Inc. [ DARA ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O DARA BIOSCIENCES, INC., 8601 SIX FORKS ROAD, SUITE 160 		3. Date of Earliest Transaction (MM/DD/YYYY)

12/4/2015
(Street)

RALEIGH, NC 27615
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   12/4/2015   12/4/2015   D    5614   D   (1) 0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option   $36.00   12/4/2015   12/4/2015   D         375    3/23/2012   3/23/2020   Common Stock   375     (2) 0   D    
Stock Option   $15.15   12/4/2015   12/4/2015   D         1000    8/2/2011   4/1/2021   Common Stock   1000     (2) 0   D    
Stock Option   $10.25   12/4/2015   12/4/2015   D         2000    9/15/2012   9/15/2021   Common Stock   2000     (2) 0   D    
Stock Option   $6.55   12/4/2015   12/4/2015   D         12000    12/27/2011   12/27/2021   Common Stock   12000     (2) 0   D    
Stock Option   $5.00   12/4/2015   12/4/2015   D         10000    12/4/2015   5/15/2022   Common Stock   10000     (2) 0   D    
Stock Option   $3.75   12/4/2015   12/4/2015   D         12000    5/10/2014   5/10/2023   Common Stock   12000     (2) 0   D    
Stock Option   $1.17   12/4/2015   12/4/2015   D         38462    5/19/2015   5/19/2024   Common Stock   38462     (2) 0   D    
Stock Option   $.79   12/4/2015   12/4/2015   D         32000    2/9/2015   2/9/2025   Common Stock   32000     (2) 0   D    
Stock Option   $.69   12/4/2015   12/4/2015   D         21739    9/19/2015   5/19/2025   Common Stock   21739     (2) 0   D    
Stock Option   $.86   12/4/2015   12/4/2015   D         10901    11/15/2015   9/1/2025   Common Stock   10901     (2) 0   D    
Preferred Stock   $0   12/4/2015   12/4/2015   D         10    6/4/2014     (4) Common Stock   9009     (5) 0   D    
Warrants   $1.67   12/4/2015   12/4/2015   D         4505    6/4/2014   6/4/2019   Common Stock   4505     (3) 0   D    

Explanation of Responses:
( 1)  Common stock disposed of pursuant to the Agreement and Plan of Merger among DARA BioSciences, Inc. (DARA) and Midatech Pharma PLC (Midatech) and certain other parties thereto, whereby each share of common stock of DARA was converted into (i) 0.136 American Depository Receipts (Midatech ADRs), with each Midatech ADR representing two Midatech ordinary shares, plus (ii) one contingent value right representing the right to receive contingent payments if specified milestones are achieved within agreed time periods, plus (iii) cash in lieu of fractional Midatech ADRs. The closing price of the Midatech ordinary shares on December 4, 2015, the effective date of the merger was ?2.65.
( 2)  These options were assumed by Midatech in connection with the Merger and replaced with options to purchase 0.136 Midatech ADRs for each DARA option held, at an exercise price equal to the exercise price of the applicable DARA option divided by 0.136.
( 3)  These warrants were assumed by Midatech in connection with the Merger and replaced with warrants to purchase 0.136 Midatech ADRs for each warrant held at an exercise price equivalent to the exercise price of a DARA option divided by 0.136.
( 4)  These preferred shares have no expiration date.
( 5)  These preferred shares were purchased by Midatech pursuant to the merger agreement for $1,000 per share for total consideration of $10,000.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
COCHRANE HAYWOOD D
C/O DARA BIOSCIENCES, INC.
8601 SIX FORKS ROAD, SUITE 160
RALEIGH, NC 27615 		X



Signatures
/s/Haywood D. Cochrane 12/7/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
(MM) (NASDAQ:DARA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos (MM).
(MM) (NASDAQ:DARA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos (MM).